Vehicle Safety
Recalls Search 320,000+ NHTSA safety recalls Complaints 2.1M+ consumer safety complaints TSBs 4.7M technical service bulletins VIN Lookup Decode any vehicle VIN instantly OBD Codes 12,000+ diagnostic trouble codes Fuel Economy EPA MPG data for all vehicles Safety Ratings 11,700+ NHTSA crash test ratings Investigations 5,300+ NHTSA defect investigations Statistics Recall trends & safety analysis
Consumer Safety
Product Safety 9,700+ CPSC product recalls Food Safety 28,600+ FDA food recalls Pet Safety 1.3M FDA animal adverse events Drug Safety 17,500+ FDA drug recalls Device Safety 38,400+ FDA device recalls Workplace Safety 102,900+ OSHA injury reports Brand History Cross-category recall lookup by company
Infrastructure
Bridge Safety 624,000 bridge inspections Aviation Safety 30,000+ NTSB aviation events Dam Safety 92,600 dam safety records Water Safety 433,000+ public water systems Railroad Safety 438,000+ rail crossings Pipeline Safety 8,800+ pipeline incidents
Public Health
Nursing Homes 14,700 CMS rated facilities Environmental 80,000+ hazardous sites & releases

Browse Drug Recalls

2,097 FDA drug safety recalls.

FDA Drug Recall Enforcement Database

Browse 2,097 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.

Drug Safety Recalls

Browse 2,097 FDA drug recalls in NJ.

Clear
DateProductReasonClassFirm
Oct 22, 2019 Estradiol Vaginal Inserts USP, 10 mcg, packaged in a) 8-count Vaginal Inserts... Defective Delivery System: complaints for difficulty in pushing the plunger of the applicator. Class II Glenmark Pharmaceuticals Inc., USA
Oct 22, 2019 Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219,... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Sanofi-Aventis U.S. LLC
Oct 22, 2019 Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Sanofi-Aventis U.S. LLC
Oct 22, 2019 Regular Strength Zantac 75 mg, Distributed by: Chattem, Inc., a Sanofi Compan... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Sanofi-Aventis U.S. LLC
Oct 22, 2019 Cool Mint Tablets Maximum Strength Zantac 150 mg Sanofi Distributed by: Chatt... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Sanofi-Aventis U.S. LLC
Oct 17, 2019 Bimatoprost Ophthalmic Solution 0.03%, Rx Only, For Topical Application to th... Labeling: Incorrect or missing package insert. Class III Sandoz Inc
Oct 17, 2019 Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Ste... Labeling: Incorrect or missing package insert. Class III Sandoz Inc
Oct 17, 2019 Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension, Rx... Labeling: Incorrect or missing package insert. Class III Sandoz Inc
Oct 1, 2019 Ranitidine Tablets, USP 75 mg, a.) 30 count bottles (NDC 69842-871-30) b.) 80... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 71713-203-02), b.)9... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Dr. Reddy's Ranitidine Capsules, USP 300 mg, a.) 30 count bottles (NDC 55111-... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 0363-0010-34), b.) ... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Dr. Reddy's Ranitidine Tablets, USP 75 mg, 60 count bottles, NDC 55111-131-60... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Dr. Reddy's Ranitidine Tablets, USP 150 mg, 24 count bottles, NDC 55111-404-3... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Dr. Reddy's: Ranitidine Capsules 150 mg, Rx a.) 60 count bottles (NDC 55111-... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 95 count bottles (NDC 43598-808-62), b.) ... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, 190 count bottles (2x95) Tray (Sam's Club) OT... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 30142-505-34), b.) ... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 75 mg, a.) 30- count bottles (NDC 0363-0131-30), b.) ... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 63868-480-24), b.) ... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC. CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger) CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, 40 count bottles, NDC 11673-849-40 (Target) OTC. CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets 75 mg, a.) 30 count bottles (NDC 63868-482-30), 60 count b... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Oct 1, 2019 Ranitidine Tablets, USP 150 mg, a.) 65 count bottles (NDC 49035-404-61) b.) 1... CGMP Deviations: Presence of NDMA impurity detected in product. Class II Dr. Reddy's Laboratories, Inc.
Sep 23, 2019 Ranitidine Tablets USP,150 mg, 8-count bottles, Distributed by: Dolgencorp,... CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles... Class III AuroMedics Pharma LLC
Sep 23, 2019 Sandoz Ranitidine Hydrochloride Capsules 300mg 30 Capsules Rx Only Manufactur... CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (N... Class II Sandoz, Inc
Sep 23, 2019 Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manu... Superpotent Class II Macleods Pharma Usa Inc
Sep 23, 2019 Sandoz Ranitidine Hydrochloride Capsules 150mg 500 Capsules Rx Only Manufactu... CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (N... Class II Sandoz, Inc
Sep 23, 2019 Sandoz Ranitidine Hydrochloride Capsules 150mg 60 Capsules Rx Only Manufactur... CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (N... Class II Sandoz, Inc
Sep 19, 2019 Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx O... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in... Class II Torrent Pharma Inc.
Sep 19, 2019 Losartan Potassium Tablets, USP 50mg, 1000 tablets per bottle, Rx Only, Manuf... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in... Class II Torrent Pharma Inc.
Sep 19, 2019 Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 tablets ... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in... Class II Torrent Pharma Inc.
Sep 19, 2019 Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate... Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for wei... Class II Aurobindo Pharma USA Inc.
Sep 19, 2019 Losartan Potassium/ Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 tablets p... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in... Class II Torrent Pharma Inc.
Sep 13, 2019 Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, pac... Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syring... Class II GUERBET LLC
Sep 13, 2019 Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefille... Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syring... Class III GUERBET LLC
Sep 6, 2019 Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in... Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities de... Class II Torrent Pharma Inc.
Sep 6, 2019 Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 coun... GMP Deviation: lot not intended for commercial distribution. Class III Teva Pharmaceuticals USA
Aug 29, 2019 Oxaliplatin Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceutical ... cGMP Deviations: Potential glass contamination Class II Johnson Matthey Inc.
Aug 29, 2019 Cisplatin Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceutical Ma... cGMP Deviations: Potential glass contamination Class II Johnson Matthey Inc.
Aug 29, 2019 Fentanyl Citrate Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceut... cGMP Deviations: Potential glass contamination Class II Johnson Matthey Inc.
Aug 23, 2019 Allergy Relief (Fexofenadine Hydrochrloride) Tablets USP, 180 mg, packaged in... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Allergy Relief (Fexofenadine HCl) tablets USP, 180 mg, 15-count cartons, equa... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Fexofenadine Hydrochrloride Tablets USP, 180 mg, 100-count bottle, Distribute... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carto... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Allergy (Fexofenadine Hydrochloride) Tablets USP, 180 mg, 30-count bottles, D... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Allergy Relief (fexofenadine hydrochrloride) tablets, 180 mg, 5-count carton,... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC
Aug 23, 2019 Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK; Manufactured for: Au... Failed Impurities/Degradation Specifications Class II Aurolife Pharma, LLC

Frequently Asked Questions

When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.

The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.

Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.